{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T18:48:35Z","timestamp":1720723715185},"reference-count":10,"publisher":"EDP Sciences","license":[{"start":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T00:00:00Z","timestamp":1554249600000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/www.edpsciences.org\/en\/authors\/copyright-and-licensing"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Sci (Paris)"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:p>L\u2019alglucosidase alfa ou Myozyme<jats:sup>\u00ae<\/jats:sup> reste le premier m\u00e9dicament innovant disponible pour traiter une myopathie de l\u2019adulte. Cette exp\u00e9rience originelle est riche d\u2019enseignements tant sur le plan de la recherche que de la pratique clinique. M\u00e9thodologie des essais, mise en \u0153uvre du traitement au sein d\u2019un service hospitalier, contribution du registre des patients, dans tous ces domaines l\u2019exp\u00e9rience acquise peut \u00eatre capitalis\u00e9e pour pr\u00e9parer l\u2019arriv\u00e9e d\u2019autres innovations th\u00e9rapeutiques.<\/jats:p>","DOI":"10.1051\/medsci\/2019021","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T13:35:04Z","timestamp":1554298504000},"page":"18-21","source":"Crossref","is-referenced-by-count":0,"special_numbering":"Hors s\u00e9rie n\u00b0 1","title":["Forme adulte de la maladie de Pompe : les le\u00e7ons du Myozyme<sup>\u00ae<\/sup>"],"prefix":"10.1051","volume":"35","author":[{"given":"Pascal","family":"Lafor\u00eat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"250","published-online":{"date-parts":[[2019,4,3]]},"reference":[{"key":"R1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0167-4781(96)00093-0","volume":"1308","author":"Bijvoet","year":"1996","journal-title":"Biochim Biophys Acta"},{"key":"R2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1023\/A:1010383421286","volume":"24","author":"Van den Hout","year":"2001","journal-title":"J Inherit Metab Dis"},{"key":"R3","first-page":"132","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet Med"},{"key":"R4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/ana.20019","volume":"55","author":"Winkel","year":"2004","journal-title":"Ann Neurol"},{"key":"R5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"R6","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","volume":"148","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"key":"R7","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N Engl J Med"},{"key":"R8","unstructured":"Orlikowski D, Lafor\u00eat P, Pellegrini N, et al. Effects of one year enzyme replacement therapy in severe form of late onset pompe disease. Severe late onset treatment study (French slots). Congr\u00e8s international de myologie. Myology 2008. Marseille : Abstracts book, mai 2008, p. 355."},{"key":"R9","unstructured":"Haute autorit\u00e9 de sant\u00e9. Avis du 22 mars 2017 de la Commission de la transparence - Myozyme (sur www.has-sante.fr)."},{"key":"R10","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.nmd.2015.04.006","volume":"25","author":"Schoser","year":"2015","journal-title":"Neuromuscul Disord"}],"container-title":["m\u00e9decine\/sciences"],"original-title":[],"link":[{"URL":"https:\/\/www.medecinesciences.org\/10.1051\/medsci\/2019021\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T19:18:39Z","timestamp":1584645519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.medecinesciences.org\/10.1051\/medsci\/2019021"}},"subtitle":["Utilisation clinique des traitements innovants, repositionn\u00e9s ou hors AMM : le v\u00e9cu du terrain (1)"],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":10,"alternative-id":["medsci190021s"],"URL":"https:\/\/doi.org\/10.1051\/medsci\/2019021","relation":{},"ISSN":["0767-0974","1958-5381"],"issn-type":[{"value":"0767-0974","type":"print"},{"value":"1958-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}